問卷

TPIDB > Search Result

Search Result

篩選

List

88Cases

2020-03-10 - 2027-03-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-04-01 - 2029-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-03-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-08-01 - 2032-03-02

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2027-08-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2023-09-30 - 2026-06-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2017-01-01 - 2020-12-31

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-06-01 - 2023-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2015-12-10 - 2019-12-31

IIT

Phase II

A PHASE II, OPEN LABEL, MULTICENTER STUDY OF BEVACIZUMAB IN COMBINATION WITH ERLOTINIB VERSUS ERLOTINIB ALONE IN PATIENTS WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES.
  • Condition/Disease

    NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES

  • Test Drug

    (1)Avastin; (2) Erlotinib

Participate Sites
3Sites

Recruiting3Sites